Maze Therapeutics, Inc. (MAZE) Fair Value 2026

MAZE · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 10 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, Maze Therapeutics, Inc. (MAZE) trades at $29.39, approximately 189% above CirclFi’s Bayesian DCF fair value of $10.17. QOC: 6.3/10. 10/13 models active.

Key Facts

Ticker
MAZE
Price
$29.39
Quality Score
6.3/10
Value Trap Risk
—/100
Models Active
10/13
Last Updated
Strength: 10 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Maze Therapeutics, Inc. (MAZE) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, Maze Therapeutics, Inc. (MAZE) appears overvalued as of : the median of 10 independent fair value estimates is $11.96, 59.3% below the current price of $29.39. Estimates range from $0.34 to $31.98. MAZE scores 6.3/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Maze Therapeutics, Inc. Stock in 2026? →

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($29.39)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
 $10.17 -65.4%
CUCE Ensemble
Low Conviction
 $16.53 -43.8%
First Chicago
Low Conviction
 $1.52 -94.8%
RCMH-DCF
Medium Conviction
 $13.75 -53.2%

Unlock the Full Matrix

Access 6 additional models including ML-RIV, Dynamic NAV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is Maze Therapeutics, Inc. (MAZE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Maze Therapeutics, Inc.'s intrinsic value is estimated at $12.50, suggesting the stock is overvalued at its current price of $29.39. With 9 out of 10 models flagging downside (-57.5% average return), the market may be pricing in unsustainable growth. Notably, Regime Cross sees the most upside at +8.8% (fair value: $31.98), while Sentiment SOTP is the most conservative at -98.9% ($0.34). The spread between these extremes — +107.7% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About MAZE?

10 of 13 models are currently active for MAZE. Of these, 1 model suggests upside while 9 models suggest overvaluation. The Bayesian DCF estimates MAZE's intrinsic value at $10.17, implying -65.4% downside from the current price. See which stocks rank higher →

How Does MAZE Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, MAZE ranks #32 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

Maze Therapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is MAZE a Value Trap?

The Value Trap algorithm is not active for MAZE. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Maze Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Maze Therapeutics, Inc.'s fundamental quality profile registers 6.3/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +107.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MAZE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MAZE's 10 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Maze Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About Maze Therapeutics, Inc.

What is Maze Therapeutics, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Maze Therapeutics, Inc. (MAZE) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $10.17. The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MAZE overvalued or undervalued right now?

At $29.39, 1 of 10 active models suggest MAZE may be undervalued, while 9 indicate potential overvaluation. The median of all 10 fair value estimates is $11.96, 59.3% below the current price of $29.39 — a consensus view that MAZE is overvalued. The assessment depends on which methodology best fits Maze Therapeutics, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 6.3 mean for MAZE?

Maze Therapeutics, Inc.'s QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on MAZE?

CirclFi analyzes MAZE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is MAZE a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for MAZE at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 10-model valuation engine, Maze Therapeutics, Inc. (MAZE) has a median fair value of $11.96 — 59.3% below the current price of $29.39 — as of 2026-07-15.” Source: circlfi.com/stock/MAZE/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on MAZE.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access